163 related articles for article (PubMed ID: 37823567)
1. Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis.
Kumari P; Mamud A; Jha AN
Curr Drug Targets; 2023; 24(13):1023-1031. PubMed ID: 37823567
[TBL] [Abstract][Full Text] [Related]
2. Status of vaccine research and development of vaccines for leishmaniasis.
Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for visceral leishmaniasis: A review.
Jain K; Jain NK
J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
[TBL] [Abstract][Full Text] [Related]
4. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
Srivastava S; Shankar P; Mishra J; Singh S
Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
[TBL] [Abstract][Full Text] [Related]
5. A review on potential therapeutic targets for the treatment of leishmaniasis.
Sheikh SY; Hassan F; Shukla D; Bala S; Faruqui T; Akhter Y; Khan AR; Nasibullah M
Parasitol Int; 2024 Jun; 100():102863. PubMed ID: 38272301
[TBL] [Abstract][Full Text] [Related]
6. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
[TBL] [Abstract][Full Text] [Related]
7. Genome wide comparison of Leishmania donovani strains from Indian visceral leishmaniasis and para-kala-azar dermal leishmaniasis patients.
Sarraf NR; Mukhopadhyay S; Banerjee A; Das AK; Roy S; Chakrabarti S; Manna M; Saha P
Acta Trop; 2021 Nov; 223():106086. PubMed ID: 34389331
[TBL] [Abstract][Full Text] [Related]
8. Progress in the Mathematical Modelling of Visceral Leishmaniasis.
Rock KS; Quinnell RJ; Medley GF; Courtenay O
Adv Parasitol; 2016; 94():49-131. PubMed ID: 27756459
[TBL] [Abstract][Full Text] [Related]
9. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs.
Fiuza JA; Santiago Hda C; Selvapandiyan A; Gannavaram S; Ricci ND; Bueno LL; Bartholomeu DC; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
Vaccine; 2013 Apr; 31(14):1785-92. PubMed ID: 23398933
[TBL] [Abstract][Full Text] [Related]
10. Intradermal Immunization of Leishmania donovani Centrin Knock-Out Parasites in Combination with Salivary Protein LJM19 from Sand Fly Vector Induces a Durable Protective Immune Response in Hamsters.
Fiuza JA; Dey R; Davenport D; Abdeladhim M; Meneses C; Oliveira F; Kamhawi S; Valenzuela JG; Gannavaram S; Nakhasi HL
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004322. PubMed ID: 26752686
[TBL] [Abstract][Full Text] [Related]
11. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
Pandey SC; Kumar A; Samant M
Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
Kumar A; Samant M
Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
[TBL] [Abstract][Full Text] [Related]
13. Road-map of pre-clinical treatment for Visceral Leishmaniasis.
Mazire P; Agarwal V; Roy A
Drug Dev Res; 2022 Apr; 83(2):317-327. PubMed ID: 34962315
[TBL] [Abstract][Full Text] [Related]
14. Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme.
Zijlstra EE; Alves F; Rijal S; Arana B; Alvar J
PLoS Negl Trop Dis; 2017 Nov; 11(11):e0005877. PubMed ID: 29145397
[TBL] [Abstract][Full Text] [Related]
15. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
Palatnik-de-Sousa CB; Nico D
Front Immunol; 2020; 11():204. PubMed ID: 32210953
[TBL] [Abstract][Full Text] [Related]
16. Xenodiagnosis to evaluate the infectiousness of humans to sandflies in an area endemic for visceral leishmaniasis in Bihar, India: a transmission-dynamics study.
Singh OP; Tiwary P; Kushwaha AK; Singh SK; Singh DK; Lawyer P; Rowton E; Chaubey R; Singh AK; Rai TK; Fay MP; Chakravarty J; Sacks D; Sundar S
Lancet Microbe; 2021 Jan; 2(1):e23-e31. PubMed ID: 33615281
[TBL] [Abstract][Full Text] [Related]
17. Recent patents in the treatment and prevention of leishmaniasis.
Shahid SK
Pharm Pat Anal; 2023 Sep; 12(5):237-248. PubMed ID: 38063376
[TBL] [Abstract][Full Text] [Related]
18. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
[TBL] [Abstract][Full Text] [Related]
19. Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis.
Duarte MC; Lage DP; Martins VT; Chávez-Fumagalli MA; Roatt BM; Menezes-Souza D; Goulart LR; Soto M; Tavares CA; Coelho EA
Rev Soc Bras Med Trop; 2016; 49(4):398-407. PubMed ID: 27598624
[TBL] [Abstract][Full Text] [Related]
20. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
